|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2001-2-22
|
|
pubmed:abstractText |
Low dose bacillus Calmette-Guerin (BCG) for stage TaT1 transitional cell carcinoma of the bladder has been given in various studies with the aim of decreasing side effects while maintaining the same efficacy as full dose bacillus Calmette-Guerin. However, its application in clinical practice remains controversial. We examined the ablative activity and incidence of side effects of intravesical quarter dose BCG given for a papillary marker lesion of the bladder.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0022-5347
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
165
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
401-3
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11176382-Adjuvants, Immunologic,
pubmed-meshheading:11176382-Adult,
pubmed-meshheading:11176382-Aged,
pubmed-meshheading:11176382-Aged, 80 and over,
pubmed-meshheading:11176382-BCG Vaccine,
pubmed-meshheading:11176382-Carcinoma, Transitional Cell,
pubmed-meshheading:11176382-Female,
pubmed-meshheading:11176382-Humans,
pubmed-meshheading:11176382-Male,
pubmed-meshheading:11176382-Middle Aged,
pubmed-meshheading:11176382-Neoplasm Recurrence, Local,
pubmed-meshheading:11176382-Neoplasm Staging,
pubmed-meshheading:11176382-Postoperative Care,
pubmed-meshheading:11176382-Urinary Bladder Neoplasms
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.
|
